Shukra Pharmaceuticals Limited share price

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

• Shukra Pharmaceuticals Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹3,048 crore.
• It trades at 88.3 times its last 12 months' earnings and 32.9 times book value.
• Revenue grew -1.2% a year over the last 4 years, profit 71.1% a year.
• Return on equity was 28.9% and return on capital employed 31.7% in the latest year.
• Debt was 0.06 times shareholders' equity.
• The share price is 8.7% below its 52-week high.
• Promoters and insiders hold about 88.7%; institutions about 0.0%.

Shukra Pharmaceuticals Limited engages in the manufacturing, marketing, and export of pharmaceutical formulations in India and internationally. The company offers various products, such as antibiotics, anti biotics, macrolides, quinolones, anti bacterial, anti fungal, anti malarial, anti viral, anti protozoal, anti anthelmintic, sedative and tranquilliser, anti depressant, anti manic, anti emetic, anti ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti tuberculosis, vitamin products, anti allergics, corticosteroids, hyper and hypoglycemic, and other products. It provides its products in ampoules, capsules, vials, and tablet forms. In addition, the company provides laboratory services; and surgical robots, diabetes technologies, cardiac sciences, advanced surgical and diagnostic solutions, imaging and critical care, medical simulations, wound care, boron neutron capture t…

Head office

Ahmedabad

HealthcareDrug Manufacturers - Specialty & Generic

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Consolidated figures in ₹ crore, as at 31 March

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Consolidated figures in ₹ crore, financial years ending March

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Filings made by the company with NSE; documents open on NSE's website.

Ex-dividend date

21 Sep 2026

Latest quarter

30 Jun 2026

Financial year end

31 Mar 2026

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.